Skip to main content
Top
Published in: BMC Complementary Medicine and Therapies 1/2023

Open Access 01-12-2023 | Lung Cancer | Research

Decoding the key compounds and mechanism of Shashen Maidong decoction in the treatment of lung cancer

Authors: Jieqi Cai, Yupeng Chen, Kexin Wang, Yi Li, Jie Wu, Hailang Yu, Qingping Li, Qi Wu, Wei Meng, Handuo Wang, Aiping Lu, Mianbo Huang, Genxia Wei, Daogang Guan

Published in: BMC Complementary Medicine and Therapies | Issue 1/2023

Login to get access

Abstract

Background

Lung cancer is a malignant tumour with the fastest increase in morbidity and mortality around the world. The clinical treatments available have significant side effects, thus it is desirable to identify alternative modalities to treat lung cancer. Shashen Maidong decoction (SMD) is a commonly used traditional Chinese medicine (TCM) formula for treating lung cancer in the clinic. While the key functional components (KFC) and the underlying mechanisms of SMD treating lung cancer are still unclear.

Methods

We propose a new integrated pharmacology model, which combines a novel node-importance calculation method and the contribution decision rate (CDR) model, to identify the KFC of SMD and to deduce their mechanisms in the treatment of lung cancer.

Results

The enriched effective Gene Ontology (GO) terms selected from our proposed node importance detection method could cover 97.66% of enriched GO terms of reference targets. After calculating CDR of active components in key functional network, the first 82 components covered 90.25% of the network information, which were defined as KFC. 82 KFC were subjected to functional analysis and experimental validation. 5–40 μM protocatechuic acid, 100–400 μM paeonol or caffeic acid exerted significant inhibitory activity on the proliferation of A549 cells. The results show that KFC play an important therapeutic role in the treatment of lung cancer by targeting Ras, AKT, IKK, Raf1, MEK, and NF-κB in the PI3K-Akt, MAPK, SCLC, and NSCLC signaling pathways active in lung cancer.

Conclusions

This study provides a methodological reference for the optimization and secondary development of TCM formulas. The strategy proposed in this study can be used to identify key compounds in the complex network and provides an operable test range for subsequent experimental verification, which greatly reduces the experimental workload.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.PubMedCrossRef Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.PubMedCrossRef
2.
go back to reference Ortiz-Cuaran S, Scheffler M, Plenker D, et al. Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors. Clin Cancer Res. 2016;22(19):4837–47.PubMedCrossRef Ortiz-Cuaran S, Scheffler M, Plenker D, et al. Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors. Clin Cancer Res. 2016;22(19):4837–47.PubMedCrossRef
3.
go back to reference Lin YT, Chen JS, Liao WY, et al. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations. Int J Cancer. 2019;144(11):2887–96.PubMedCrossRef Lin YT, Chen JS, Liao WY, et al. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations. Int J Cancer. 2019;144(11):2887–96.PubMedCrossRef
4.
go back to reference Cheng G, Zhang L. Adverse events related to bevacizumab and the management principles in non-small cell lung cancer. Zhongguo Fei Ai Za Zhi. 2010;13(6):563–7.PubMed Cheng G, Zhang L. Adverse events related to bevacizumab and the management principles in non-small cell lung cancer. Zhongguo Fei Ai Za Zhi. 2010;13(6):563–7.PubMed
5.
go back to reference Zhao Z, Ni Y, Li L, Xin T. Acquired drug resistance mechanism of osimertinib in the targeted therapy of non-small cell lung cancer. Zhongguo Fei Ai Za Zhi. 2020;23(4):274–81.PubMed Zhao Z, Ni Y, Li L, Xin T. Acquired drug resistance mechanism of osimertinib in the targeted therapy of non-small cell lung cancer. Zhongguo Fei Ai Za Zhi. 2020;23(4):274–81.PubMed
6.
go back to reference Su XL, Wang JW, Che H, et al. Clinical application and mechanism of traditional Chinese medicine in treatment of lung cancer. Chin Med J (Engl). 2020;133(24):2987–97.PubMedCrossRef Su XL, Wang JW, Che H, et al. Clinical application and mechanism of traditional Chinese medicine in treatment of lung cancer. Chin Med J (Engl). 2020;133(24):2987–97.PubMedCrossRef
7.
go back to reference Zhao B, Hui X, Jiao L, et al. A TCM formula YYWY inhibits tumor growth in non-small cell lung cancer and enhances immune-response through facilitating the maturation of dendritic cells. Front Pharmacol. 2020;11:798.PubMedPubMedCentralCrossRef Zhao B, Hui X, Jiao L, et al. A TCM formula YYWY inhibits tumor growth in non-small cell lung cancer and enhances immune-response through facilitating the maturation of dendritic cells. Front Pharmacol. 2020;11:798.PubMedPubMedCentralCrossRef
8.
go back to reference Zheng X, Wang W, Wang G, Liu S. Could Jinfukang alleviate the chemotherapy-related adverse effects in non-small cell lung cancer patients?: A protocol for a double-blind, randomized controlled trial. Medicine (Baltimore). 2021;100(28):e25002.PubMedCrossRef Zheng X, Wang W, Wang G, Liu S. Could Jinfukang alleviate the chemotherapy-related adverse effects in non-small cell lung cancer patients?: A protocol for a double-blind, randomized controlled trial. Medicine (Baltimore). 2021;100(28):e25002.PubMedCrossRef
9.
go back to reference Xu ZY, Jin CJ, Zhou CC, et al. Treatment of advanced non-small-cell lung cancer with Chinese herbal medicine by stages combined with chemotherapy. J Cancer Res Clin Oncol. 2011;137(7):1117–22.PubMedCrossRef Xu ZY, Jin CJ, Zhou CC, et al. Treatment of advanced non-small-cell lung cancer with Chinese herbal medicine by stages combined with chemotherapy. J Cancer Res Clin Oncol. 2011;137(7):1117–22.PubMedCrossRef
10.
go back to reference He M, Luo Y, Chen L, et al. Shashen maidong decoction: the effect of TNF-alpha and IL-6 on lung cancer cachexia based on cancer toxicity theory. Am J Transl Res. 2021;13(6):6752–8.PubMedPubMedCentral He M, Luo Y, Chen L, et al. Shashen maidong decoction: the effect of TNF-alpha and IL-6 on lung cancer cachexia based on cancer toxicity theory. Am J Transl Res. 2021;13(6):6752–8.PubMedPubMedCentral
11.
go back to reference Huang QH, Liang YJ, Chen N, Du XT. Effect of Shashen Maidong decoction on tumor marker levels in patients with non-small cell lung cancer. Mod Med Health Res Electron J. 2021;5(12):87–9. Huang QH, Liang YJ, Chen N, Du XT. Effect of Shashen Maidong decoction on tumor marker levels in patients with non-small cell lung cancer. Mod Med Health Res Electron J. 2021;5(12):87–9.
12.
go back to reference Wang Y, Yang SY, Pan YN, et al. lnfluences of Shashen Maidong decoction-containing serum combined with cisplatin on expressions of E-cadherin and snail in lung adenocarcinoma A549 cells. Chin Arch Tradit Chin Med. 2021;39(08):62–5. Wang Y, Yang SY, Pan YN, et al. lnfluences of Shashen Maidong decoction-containing serum combined with cisplatin on expressions of E-cadherin and snail in lung adenocarcinoma A549 cells. Chin Arch Tradit Chin Med. 2021;39(08):62–5.
13.
go back to reference Xu WW, Liu CY. Effect of Shashen Maidong decoction combined with cisplatin on proliferation of lung cancer cell line A549 and expressions of Smad7 and TGF-β1 protein. Liaoning J Tradit Chin Med. 2020;47(05):144–7. Xu WW, Liu CY. Effect of Shashen Maidong decoction combined with cisplatin on proliferation of lung cancer cell line A549 and expressions of Smad7 and TGF-β1 protein. Liaoning J Tradit Chin Med. 2020;47(05):144–7.
14.
go back to reference Chen J, Yuan J, Zhou L, et al. Regulation of different components from ophiopogon japonicus on autophagy in human lung adenocarcinoma A549Cells through PI3K/Akt/mTOR signaling pathway. Biomed Pharmacother. 2017;87:118–26.PubMedCrossRef Chen J, Yuan J, Zhou L, et al. Regulation of different components from ophiopogon japonicus on autophagy in human lung adenocarcinoma A549Cells through PI3K/Akt/mTOR signaling pathway. Biomed Pharmacother. 2017;87:118–26.PubMedCrossRef
15.
go back to reference Wu J, Gao W, Song Z, et al. Anticancer activity of polysaccharide from Glehnia littoralis on human lung cancer cell line A549. Int J Biol Macromol. 2018;106:464–72.PubMedCrossRef Wu J, Gao W, Song Z, et al. Anticancer activity of polysaccharide from Glehnia littoralis on human lung cancer cell line A549. Int J Biol Macromol. 2018;106:464–72.PubMedCrossRef
16.
go back to reference Li S, Zhou X, Xiong H. Clinical study of Shashenmaidong decoction in the treatment of clinical study of Shashenmaidong decoction in the treatment of clinical study of Shashenmaidong decoction in the treatment of clinical study of Shashenmaidong decoction in the treatment of radiation pneumonitis. Acta Chin Med. 2015;30(03):328–9. Li S, Zhou X, Xiong H. Clinical study of Shashenmaidong decoction in the treatment of clinical study of Shashenmaidong decoction in the treatment of clinical study of Shashenmaidong decoction in the treatment of clinical study of Shashenmaidong decoction in the treatment of radiation pneumonitis. Acta Chin Med. 2015;30(03):328–9.
17.
go back to reference Liu M, Wu YL, Zeng R. Observation on the effect of Jiajian Shashen Maidong decoction combined with chemotherapy in the treatment of non-small cell lung cancer. Chin J Clin Rational Drug Use. 2020;13(11):53–4. Liu M, Wu YL, Zeng R. Observation on the effect of Jiajian Shashen Maidong decoction combined with chemotherapy in the treatment of non-small cell lung cancer. Chin J Clin Rational Drug Use. 2020;13(11):53–4.
18.
go back to reference Wang KX, Gao Y, Lu C, et al. Uncovering the complexity mechanism of different formulas treatment for rheumatoid arthritis based on a novel network pharmacology model. Front Pharmacol. 2020;11:1035.PubMedPubMedCentralCrossRef Wang KX, Gao Y, Lu C, et al. Uncovering the complexity mechanism of different formulas treatment for rheumatoid arthritis based on a novel network pharmacology model. Front Pharmacol. 2020;11:1035.PubMedPubMedCentralCrossRef
19.
go back to reference Yang L, Fan L, Wang K, et al. Analysis of molecular mechanism of erxian decoction in treating osteoporosis based on formula optimization model. Oxid Med Cell Longev. 2021;2021:6641838.PubMedPubMedCentral Yang L, Fan L, Wang K, et al. Analysis of molecular mechanism of erxian decoction in treating osteoporosis based on formula optimization model. Oxid Med Cell Longev. 2021;2021:6641838.PubMedPubMedCentral
20.
go back to reference Pinero J, Ramirez-Anguita JM, Sauch-Pitarch J, et al. The DisGeNET knowledge platform for disease genomics: 2019 update. Nucleic Acids Res. 2020;48(D1):D845–55.PubMed Pinero J, Ramirez-Anguita JM, Sauch-Pitarch J, et al. The DisGeNET knowledge platform for disease genomics: 2019 update. Nucleic Acids Res. 2020;48(D1):D845–55.PubMed
22.
go back to reference Xu HY, Zhang YQ, Liu ZM, et al. ETCM: an encyclopaedia of traditional Chinese medicine. Nucleic Acids Res. 2019;47(D1):D976–82.PubMedCrossRef Xu HY, Zhang YQ, Liu ZM, et al. ETCM: an encyclopaedia of traditional Chinese medicine. Nucleic Acids Res. 2019;47(D1):D976–82.PubMedCrossRef
23.
go back to reference Wu Y, Zhang F, Yang K, et al. SymMap: an integrative database of traditional Chinese medicine enhanced by symptom mapping. Nucleic Acids Res. 2019;47(D1):D1110–7.PubMedCrossRef Wu Y, Zhang F, Yang K, et al. SymMap: an integrative database of traditional Chinese medicine enhanced by symptom mapping. Nucleic Acids Res. 2019;47(D1):D1110–7.PubMedCrossRef
26.
go back to reference Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7:42717.PubMedPubMedCentralCrossRef Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7:42717.PubMedPubMedCentralCrossRef
27.
go back to reference Gfeller D, Grosdidier A, Wirth M, Daina A, Michielin O, Zoete V. SwissTargetPrediction: a web server for target prediction of bioactive small molecules. Nucleic Acids Res. 2014;42(Web Server issue):W32–8.PubMedPubMedCentralCrossRef Gfeller D, Grosdidier A, Wirth M, Daina A, Michielin O, Zoete V. SwissTargetPrediction: a web server for target prediction of bioactive small molecules. Nucleic Acids Res. 2014;42(Web Server issue):W32–8.PubMedPubMedCentralCrossRef
28.
go back to reference Liu X, Vogt I, Haque T, Campillos M. HitPick: a web server for hit identification and target prediction of chemical screenings. Bioinformatics. 2013;29(15):1910–2.PubMedCrossRef Liu X, Vogt I, Haque T, Campillos M. HitPick: a web server for hit identification and target prediction of chemical screenings. Bioinformatics. 2013;29(15):1910–2.PubMedCrossRef
29.
go back to reference Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, Shoichet BK. Relating protein pharmacology by ligand chemistry. Nat Biotechnol. 2007;25(2):197–206.PubMedCrossRef Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, Shoichet BK. Relating protein pharmacology by ligand chemistry. Nat Biotechnol. 2007;25(2):197–206.PubMedCrossRef
30.
go back to reference Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607–13.PubMedCrossRef Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607–13.PubMedCrossRef
31.
go back to reference Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–504.PubMedPubMedCentralCrossRef Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–504.PubMedPubMedCentralCrossRef
35.
go back to reference Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2023;51(D1):D587–92.PubMedCrossRef Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2023;51(D1):D587–92.PubMedCrossRef
36.
go back to reference Wickham H. ggplot2: Elegant Graphics for Data Analysis. New York: Springer-Verlag; 2016. Wickham H. ggplot2: Elegant Graphics for Data Analysis. New York: Springer-Verlag; 2016.
38.
go back to reference Zhang L, Chen WX, Li LL, et al. Paeonol suppresses proliferation and motility of non-small-cell lung cancer cells by disrupting STAT3/NF-kappaB signaling. Front Pharmacol. 2020;11:572616.PubMedPubMedCentralCrossRef Zhang L, Chen WX, Li LL, et al. Paeonol suppresses proliferation and motility of non-small-cell lung cancer cells by disrupting STAT3/NF-kappaB signaling. Front Pharmacol. 2020;11:572616.PubMedPubMedCentralCrossRef
39.
go back to reference Lin CL, Chen RF, Chen JY, et al. Protective effect of caffeic acid on paclitaxel induced anti-proliferation and apoptosis of lung cancer cells involves NF-kappaB pathway. Int J Mol Sci. 2012;13(5):6236–45.PubMedPubMedCentralCrossRef Lin CL, Chen RF, Chen JY, et al. Protective effect of caffeic acid on paclitaxel induced anti-proliferation and apoptosis of lung cancer cells involves NF-kappaB pathway. Int J Mol Sci. 2012;13(5):6236–45.PubMedPubMedCentralCrossRef
40.
go back to reference Yin MC, Lin CC, Wu HC, Tsao SM, Hsu CK. Apoptotic effects of protocatechuic acid in human breast, lung, liver, cervix, and prostate cancer cells: potential mechanisms of action. J Agric Food Chem. 2009;57(14):6468–73.PubMedCrossRef Yin MC, Lin CC, Wu HC, Tsao SM, Hsu CK. Apoptotic effects of protocatechuic acid in human breast, lung, liver, cervix, and prostate cancer cells: potential mechanisms of action. J Agric Food Chem. 2009;57(14):6468–73.PubMedCrossRef
41.
go back to reference Sun Y. Chemical composition analysis and pharmacokinetic study of the Shasheng Maidong decoction. PhD thesis. Hebei Medical University; 2016. Sun Y. Chemical composition analysis and pharmacokinetic study of the Shasheng Maidong decoction. PhD thesis. Hebei Medical University; 2016.
43.
44.
go back to reference Tian Q, Wang L, Sun X, Zeng F, Pan Q, Xue M. Scopoletin exerts anticancer effects on human cervical cancer cell lines by triggering apoptosis, cell cycle arrest, inhibition of cell invasion and PI3K/AKT signalling pathway. J BUON. 2019;24(3):997–1002.PubMed Tian Q, Wang L, Sun X, Zeng F, Pan Q, Xue M. Scopoletin exerts anticancer effects on human cervical cancer cell lines by triggering apoptosis, cell cycle arrest, inhibition of cell invasion and PI3K/AKT signalling pathway. J BUON. 2019;24(3):997–1002.PubMed
45.
go back to reference Velli SK, Sundaram J, Murugan M, Balaraman G, Thiruvengadam D. Protective effect of vanillic acid against benzo(a)pyrene induced lung cancer in Swiss albino mice. J Biochem Mol Toxicol. 2019;33(10):e22382.PubMedCrossRef Velli SK, Sundaram J, Murugan M, Balaraman G, Thiruvengadam D. Protective effect of vanillic acid against benzo(a)pyrene induced lung cancer in Swiss albino mice. J Biochem Mol Toxicol. 2019;33(10):e22382.PubMedCrossRef
46.
go back to reference Reczynska K, Marchwica P, Khanal D, et al. Stimuli-sensitive fatty acid-based microparticles for the treatment of lung cancer. Mater Sci Eng C Mater Biol Appl. 2020;111:110801.PubMedCrossRef Reczynska K, Marchwica P, Khanal D, et al. Stimuli-sensitive fatty acid-based microparticles for the treatment of lung cancer. Mater Sci Eng C Mater Biol Appl. 2020;111:110801.PubMedCrossRef
47.
go back to reference Cai Y, Jia R, Xiong H, et al. Integrative gene expression profiling reveals that dysregulated triple microRNAs confer paclitaxel resistance in non-small cell lung cancer via co-targeting MAPT. Cancer Manag Res. 2019;11:7391–404.PubMedPubMedCentralCrossRef Cai Y, Jia R, Xiong H, et al. Integrative gene expression profiling reveals that dysregulated triple microRNAs confer paclitaxel resistance in non-small cell lung cancer via co-targeting MAPT. Cancer Manag Res. 2019;11:7391–404.PubMedPubMedCentralCrossRef
48.
go back to reference Mokhlesi A, Talkhabi M. Comprehensive transcriptomic analysis identifies novel regulators of lung adenocarcinoma. J Cell Commun Signal. 2020;14(4):453–65.PubMedPubMedCentralCrossRef Mokhlesi A, Talkhabi M. Comprehensive transcriptomic analysis identifies novel regulators of lung adenocarcinoma. J Cell Commun Signal. 2020;14(4):453–65.PubMedPubMedCentralCrossRef
49.
go back to reference Khomenko TM, Zakharenko AL, Chepanova AA, et al. Promising new inhibitors of Tyrosyl-DNA phosphodiesterase I (Tdp 1) combining 4-arylcoumarin and monoterpenoid moieties as components of complex antitumor therapy. Int J Mol Sci. 2019;21(1):126.PubMedPubMedCentralCrossRef Khomenko TM, Zakharenko AL, Chepanova AA, et al. Promising new inhibitors of Tyrosyl-DNA phosphodiesterase I (Tdp 1) combining 4-arylcoumarin and monoterpenoid moieties as components of complex antitumor therapy. Int J Mol Sci. 2019;21(1):126.PubMedPubMedCentralCrossRef
50.
go back to reference Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361(10):958–67.PubMedCrossRef Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361(10):958–67.PubMedCrossRef
51.
go back to reference Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–39.PubMedCrossRef Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–39.PubMedCrossRef
52.
go back to reference Agca CA, Kirici M, Nedzvetsky VS, Gundogdu R, Tykhomyrov AA. The effect of TIGAR knockdown on apoptotic and epithelial-mesenchymal markers expression in doxorubicin-resistant non-small cell lung cancer A549 cell lines. Chem Biodivers. 2020;17(9):e2000441.PubMed Agca CA, Kirici M, Nedzvetsky VS, Gundogdu R, Tykhomyrov AA. The effect of TIGAR knockdown on apoptotic and epithelial-mesenchymal markers expression in doxorubicin-resistant non-small cell lung cancer A549 cell lines. Chem Biodivers. 2020;17(9):e2000441.PubMed
53.
go back to reference Manabe S, Kasajima R, Murakami S, et al. Analysis of targeted somatic mutations in pleomorphic carcinoma of the lung using next-generation sequencing technique. Thoracic Cancer. 2020;11(8):2262–9.PubMedPubMedCentralCrossRef Manabe S, Kasajima R, Murakami S, et al. Analysis of targeted somatic mutations in pleomorphic carcinoma of the lung using next-generation sequencing technique. Thoracic Cancer. 2020;11(8):2262–9.PubMedPubMedCentralCrossRef
54.
go back to reference Yang W, You N, Jia M, et al. Undetectable circulating tumor DNA levels correlate with low risk of recurrence/metastasis in postoperative pathologic stage I lung adenocarcinoma patients. Lung Cancer. 2020;146:327–34.PubMedCrossRef Yang W, You N, Jia M, et al. Undetectable circulating tumor DNA levels correlate with low risk of recurrence/metastasis in postoperative pathologic stage I lung adenocarcinoma patients. Lung Cancer. 2020;146:327–34.PubMedCrossRef
55.
go back to reference Rosell R, Bivona TG, Karachaliou N. Genetics and biomarkers in personalisation of lung cancer treatment. Lancet. 2013;382(9893):720–31.PubMedCrossRef Rosell R, Bivona TG, Karachaliou N. Genetics and biomarkers in personalisation of lung cancer treatment. Lancet. 2013;382(9893):720–31.PubMedCrossRef
56.
go back to reference Chen JA, Riess JW. Optimal management of patients with advanced NSCLC harboring high PD-L1 expression and driver mutations. Curr Treat Options Oncol. 2020;21(7):60.PubMedCrossRef Chen JA, Riess JW. Optimal management of patients with advanced NSCLC harboring high PD-L1 expression and driver mutations. Curr Treat Options Oncol. 2020;21(7):60.PubMedCrossRef
57.
go back to reference Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377(9):829–38.PubMedCrossRef Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377(9):829–38.PubMedCrossRef
58.
go back to reference Verma P, Ghosh A, Ray M, Sarkar S. Lauric acid modulates cancer-associated microRNA expression and inhibits the growth of the cancer cell. Anticancer Agents Med Chem. 2020;20(7):834–44.PubMedCrossRef Verma P, Ghosh A, Ray M, Sarkar S. Lauric acid modulates cancer-associated microRNA expression and inhibits the growth of the cancer cell. Anticancer Agents Med Chem. 2020;20(7):834–44.PubMedCrossRef
59.
61.
go back to reference Wang C, Li S, Liu J, et al. Silencing of S-phase kinase-associated protein 2 enhances radiosensitivity of esophageal cancer cells through inhibition of PI3K/AKT signaling pathway. Genomics. 2020;112(5):3504–10.PubMedCrossRef Wang C, Li S, Liu J, et al. Silencing of S-phase kinase-associated protein 2 enhances radiosensitivity of esophageal cancer cells through inhibition of PI3K/AKT signaling pathway. Genomics. 2020;112(5):3504–10.PubMedCrossRef
62.
go back to reference Ueda K, Nakahara T, Akanuma K, Mori A, Sakamoto K, Ishii K. Differential effects of LY294002 and wortmannin on neurons and vascular endothelial cells in the rat retina. Pharmacol Rep. 2013;65(4):854–62.PubMedCrossRef Ueda K, Nakahara T, Akanuma K, Mori A, Sakamoto K, Ishii K. Differential effects of LY294002 and wortmannin on neurons and vascular endothelial cells in the rat retina. Pharmacol Rep. 2013;65(4):854–62.PubMedCrossRef
63.
go back to reference Yang P, Zhao J, Hou L, Yang L, Wu K, Zhang L. Vitamin E succinate induces apoptosis via the PI3K/AKT signaling pathways in EC109 esophageal cancer cells. Mol Med Rep. 2016;14(2):1531–7.PubMedPubMedCentralCrossRef Yang P, Zhao J, Hou L, Yang L, Wu K, Zhang L. Vitamin E succinate induces apoptosis via the PI3K/AKT signaling pathways in EC109 esophageal cancer cells. Mol Med Rep. 2016;14(2):1531–7.PubMedPubMedCentralCrossRef
64.
go back to reference Li C, Liu DR, Li GG, et al. CD97 promotes gastric cancer cell proliferation and invasion through exosome-mediated MAPK signaling pathway. World J Gastroenterol. 2015;21(20):6215–28.PubMedPubMedCentralCrossRef Li C, Liu DR, Li GG, et al. CD97 promotes gastric cancer cell proliferation and invasion through exosome-mediated MAPK signaling pathway. World J Gastroenterol. 2015;21(20):6215–28.PubMedPubMedCentralCrossRef
Metadata
Title
Decoding the key compounds and mechanism of Shashen Maidong decoction in the treatment of lung cancer
Authors
Jieqi Cai
Yupeng Chen
Kexin Wang
Yi Li
Jie Wu
Hailang Yu
Qingping Li
Qi Wu
Wei Meng
Handuo Wang
Aiping Lu
Mianbo Huang
Genxia Wei
Daogang Guan
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2023
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/s12906-023-03985-y

Other articles of this Issue 1/2023

BMC Complementary Medicine and Therapies 1/2023 Go to the issue